
Carisma Therapeutics Inc
NASDAQ:CARM

Intrinsic Value
The intrinsic value of one
CARM
stock under the Base Case scenario is
1.342
USD.
Compared to the current market price of 0.186 USD,
Carisma Therapeutics Inc
is
Undervalued by 86%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Carisma Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Carisma Therapeutics Inc
Balance Sheet Decomposition
Carisma Therapeutics Inc
Current Assets | 14m |
Cash & Short-Term Investments | 7.7m |
Receivables | 1.2m |
Other Current Assets | 5m |
Non-Current Assets | 2m |
PP&E | 2m |
Free Cash Flow Analysis
Carisma Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Carisma Therapeutics Inc
Revenue
|
20m
USD
|
Operating Expenses
|
-72m
USD
|
Operating Income
|
-52m
USD
|
Other Expenses
|
1.2m
USD
|
Net Income
|
-50.8m
USD
|
CARM Profitability Score
Profitability Due Diligence
Carisma Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Score
Carisma Therapeutics Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
CARM Solvency Score
Solvency Due Diligence
Carisma Therapeutics Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Score
Carisma Therapeutics Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CARM Price Targets Summary
Carisma Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
CARM
is 1.02 USD
with a low forecast of 1.01 USD and a high forecast of 1.05 USD.
Dividends
Current shareholder yield for CARM is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
CARM
stock under the Base Case scenario is
1.342
USD.
Compared to the current market price of 0.186 USD,
Carisma Therapeutics Inc
is
Undervalued by 86%.